We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

In the PURPOSE 1 study, none of the ... Participants in the lenacapavir arm received two injections every six months along with a daily placebo pill, while those in the prevention pill arm took ...

It would be an unprecedented move, in order to save time, similar to Gilead issuing licences to six generic companies in India (3), Egypt (1 ... pills (two months, because CAB-LA is taken every second ...

Lenacapavir is indicated for adults with multidrug-resistant HIV-1 strains, where existing therapies have failed due to resistance or intolerance. This subcutaneous injection - administered under ...

The drug offers an alternative to daily pills such as Gilead ... to reach 7 billion pounds ($9.1 billion) by 2026. Wall Street’s consensus estimate has put lenacapavir’s global peak sales ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

twice-yearly lenacapavir for PrEP could help address the stigma and discrimination some people may face when taking or storing oral PrEP pills, as well as potentially help increase PrEP adherence ...